Company intelligence / Profile preview

NuvioDx

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

NuvioDx is an early-stage biotechnology company focused on developing advanced liquid biopsy technologies for cancer detection and monitoring. The company leverages proprietary methods to analyze cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) with high sensitivity and specificity. By providing non-invasive diagnostic tools, NuvioDx aims to improve early cancer diagnosis, treatment selection, and minimal residual disease monitoring. Their technology is designed to integrate into clinical workflows to provide actionable insights for oncologists and patients.

Therapeutic areas: Oncology
Modalities: DiagnosticLiquid biopsy
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on NuvioDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuvioDx.

Explore the full profile